本议案尚需提交公司股东大会审议。 第十届监事会 2025 年度第四次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 康美药业股份有限公司（以下简称公司）第十届监事会 2025 年度第四次临 时会议于 2025 年 12 月 10 日以现场结合通讯表决方式召开，会议通知已于 2025 年 12 月 3 日以通讯方式向公司各位监事发出。本次会议应当出席监事 3 名，实 际出席监事 3 名，监事会主席何则正先生主持会议，本次会议的召开符合《公司 法》《公司章程》等相关文件的规定，作出的决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于取消监事会及废止<监事会议事规则>的议案》 表决结果：赞同票 3 票，反对票 0 票，弃权票 0 票。 证券代码：600518 证券简称：康美药业 编号：临2025-038 康美药业股份有限公司 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业关于取消监事会的公告》。 特此公告。 康美药业股份有限公司监事会 ...

证券代码：600518 证券简称：康美药业 编号：临2025-037 康美药业股份有限公司 第十届董事会 2025 年度第五次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 康美药业股份有限公司（以下简称公司）第十届董事会 2025 年度第五次临 时会议于 2025 年 12 月 10 日以现场结合通讯表决方式召开，会议通知已于 2025 年 12 月 3 日以通讯、邮件方式向公司各位董事发出。本次会议应当出席董事 9 名，实际出席董事 9 名，董事长赖志坚先生主持会议，公司董事会秘书、独立董 事候选人出席会议，全体监事列席会议，本次会议的召开符合《公司法》《公司 章程》等相关文件的规定，作出的决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于取消监事会及废止<监事会议事规则>的议案》 表决结果：赞同票 9 票，反对票 0 票，弃权票 0 票。 本议案尚需提交公司股东大会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业关于 ...

每经AI快讯，康美药业（SH 600518，收盘价：1.97元）12月10日晚间发布公告称，公司第十届2025年 度第五次董事会临时会议于2025年12月10日以现场结合通讯表决方式召开。会议审议了《关于修订 <董 事会议事规则> 的议案》等文件。 每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ （记者 曾健辉） 2024年1至12月份，康美药业的营业收入构成为：医药占比81.73%，其他行业占比9.1%，保健食品及食 品占比8.43%，其他业务占比0.74%。 截至发稿，康美药业市值为272亿元。 ...

南财智讯12月10日电，康美药业公告，公司董事会于近日收到独立董事骆涛先生递交的书面辞职报告。 骆涛先生因个人原因申请辞去公司第十届董事会独立董事职务，同时辞去审计委员会召集人、提名委员 会委员职务，辞职后骆涛先生将不再担任公司任何职务。根据相关规定，骆涛先生的辞职将导致公司董 事会及部分专门委员会的人员构成不符合规定，在股东大会选举产生新任独立董事前，骆涛先生仍将按 照有关法律法规和《公司章程》的规定，继续履行独立董事职责。 ...

Core Viewpoint - During the "14th Five-Year Plan" period, the Guangdong Securities Regulatory Bureau has focused on "risk prevention, strong regulation, and promoting high-quality development," achieving significant results in stabilizing and ensuring the healthy operation of the capital market, which effectively supports the development of the real economy [1] Regulatory Enforcement - The Guangdong Securities Regulatory Bureau has rigorously enforced laws against various securities and futures violations, issuing 158 penalty decisions since 2021, with fines totaling nearly 670 million yuan, thereby enhancing regulatory pressure and deterrence [2] - The bureau has adopted a "big, evil, and key" approach to enforcement, resulting in lifetime market bans for three individuals and temporary bans for eight others, while also referring 38 cases to law enforcement for suspected criminal activities [2] Focus on Information Disclosure - The bureau has maintained a high-pressure stance against violations of information disclosure by listed companies, successfully handling cases involving companies such as Blue Shield Co., Ltd. and Dinglong Culture [3] - A dual investigation approach has been implemented, addressing 13 cases of accounting firms failing to fulfill their responsibilities, thereby enhancing the role of intermediaries [3] Investor Protection - The bureau emphasizes the protection of investors' rights, with over 180 million investors in Guangdong, the largest in the country, and has implemented a multi-faceted accountability system for administrative, civil, and criminal responsibilities [4][5] - Significant compensation efforts have been made, including landmark cases such as the special representative litigation for Kangmei Pharmaceutical, which compensated 24.59 billion yuan to 52,000 investors [5] Dispute Resolution - The bureau has promoted a multi-faceted dispute resolution mechanism, successfully mediating 2,119 cases and recovering 136 million yuan for investors during the "14th Five-Year Plan" period [6] - Collaborative efforts with local courts have been established to enhance the efficiency of civil compensation lawsuits related to securities fraud [6] Cash Dividend Regulation - The bureau has enforced regulations to strengthen cash dividend policies among listed companies, resulting in nearly 120 billion yuan in dividends distributed in 2024, with a payout ratio exceeding the market average by 20 percentage points [7] Anti-Illegal Activities - The bureau has intensified efforts to combat illegal financial activities, establishing a collaborative mechanism with local governments and law enforcement to effectively clean up illegal securities activities [8][9] - Over 390 complaints related to illegal activities have been processed, recovering nearly 2 million yuan for investors, with serious cases referred to law enforcement for criminal prosecution [9]

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.2% on November 26, with Yue Wannianqing leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Top Performers - Yue Wannianqing (301111) closed at 22.06, up 20.02% with a trading volume of 142,800 shares and a transaction value of 304 million yuan [1] - Zhongheng Group (600252) closed at 2.95, up 10.07% with a trading volume of 1,291,400 shares and a transaction value of 374 million yuan [1] - ST Xiangxue (300147) closed at 9.77, up 4.27% with a trading volume of 196,000 shares [1] Underperformers - ST Changyao (300391) closed at 2.49, down 8.79% with a trading volume of 466,300 shares and a transaction value of 119 million yuan [2] - Jinhua Co. (600080) closed at 8.71, down 3.01% with a trading volume of 259,800 shares [2] - Zhongsheng Pharmaceutical (002317) closed at 25.51, down 1.77% with a trading volume of 1,682,400 shares and a transaction value of 441.9 million yuan [2] Capital Flow - The traditional medicine sector experienced a net outflow of 390 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2][3] - Major stocks like Zhongheng Group and Yue Wannianqing had significant net inflows from retail investors, while institutional investors showed a net outflow [3]

Core Viewpoint - The company is focused on developing a shareholder return plan based on actual operating conditions, cash flow levels, and future development needs, while also addressing ongoing legal disputes related to past management [1][2]. Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 3.96 billion, a year-on-year increase of 2.22%, and a net profit attributable to shareholders of 13 million, a significant year-on-year increase of 160.84% [1]. Corporate Restructuring - The company completed its restructuring in 2021, with the controlling shareholder changing to Guangdong Shennongshi Enterprise Management Partnership (Limited Partnership). As of July 4, 2024, the company has removed "other risk warnings" and achieved "delisting" from such warnings [1]. Legal Matters - The company is actively pursuing legal rights regarding claims against former management and related parties, with ongoing court hearings and no final judgment received yet [1]. Debt and Liabilities - In 2022, the company recognized a contingent liability of 609 million based on the value of mortgaged properties related to the Bohai case, which reduced the net profit attributable to shareholders for that year by the same amount [2]. Core Business Development - The company identifies traditional Chinese medicine (TCM) decoction pieces as its most competitive product, with eight modern production bases established across various provinces, capable of producing over 1,000 types and more than 20,000 specifications [2]. Strategic Planning - The company has a strategic plan termed "12355," positioning itself as a smart TCM health brand, focusing on the full chain of TCM decoction pieces and providing health services, with five main business sectors: TCM, medical care, TCM city, health products, and pharmaceutical commerce [3]. Innovation and Intellectual Property - As of mid-2025, the company holds over 600 intellectual property rights, including patents and software copyrights, with 36 national patent products and 13 high-tech products recognized by Guangdong Province [3].

Core Viewpoint - The company, Kangmei Pharmaceutical Co., Ltd., will hold a Q3 2025 earnings presentation on November 21, 2025, to discuss its operational results and financial status with investors [2][3][4]. Group 1: Meeting Details - The earnings presentation is scheduled for November 21, 2025, from 15:00 to 16:00 [4]. - The location of the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website [4]. - The format of the meeting will be an online interactive session [3][4]. Group 2: Participation Information - Investors can submit questions from November 14 to November 20, 2025, through the Roadshow Center website or via the company's email [5]. - During the earnings presentation, the company will address commonly asked questions from investors [3][5]. Group 3: Participants - Key participants in the meeting will include the Chairman, General Manager, and other senior executives of the company [4]. Group 4: Contact Information - For inquiries, investors can contact the Securities Affairs Department at the provided phone number [6]. Group 5: Additional Information - After the earnings presentation, investors can view the meeting's details and main content on the Roadshow Center website [7].

Core Viewpoint - Kangmei Pharmaceutical Co., Ltd. is set to hold a Q3 2025 earnings presentation on November 21, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation will take place on November 21, 2025, from 15:00 to 16:00 [2][7]. - Investors can submit questions from November 14 to November 20, 2025, via the Shanghai Stock Exchange Roadshow Center or through the company's email [2][5]. - The presentation will be conducted in an interactive online format, allowing for real-time communication with investors [3][6]. Group 2: Participants and Contact Information - Key participants in the earnings presentation include Chairman Lai Zhijian, General Manager Ou Guoxiong, and other senior executives [4]. - For inquiries, investors can contact the Securities Affairs Department at 0755-33187777 or via email at kangmei@kangmei.com.cn [8].

证券代码：600518 证券简称：康美药业 编号：临2025-036 康美药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 21 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司董事长赖志坚先生，董事兼总经理欧国雄先生，董事、副总经理兼董事 会秘书周云峰先生，独立董事骆涛先生，副总经理兼财务总监宫贵博先生。 投资者可于 2025 年 11 月 14 日（星期五）至 11 月 20 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进 ...